Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

被引：18
作者：
Cowey, C. Lance [1 ]
机构：
[1] US Oncol Res, Baylor Sammons Canc Ctr, Texas Oncol, PA, Dallas, TX 75246 USA
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2013年 / 7卷
关键词：
tivozanib; AV-951; metastatic renal cell carcinoma; RCC; VEGF inhibitor; targeted therapy; angiogenesis inhibitor; INTERFERON-ALPHA; DOUBLE-BLIND; EVEROLIMUS; SORAFENIB; SUNITINIB; SURVIVAL; EFFICACY; SAFETY; AV-951; TRIAL;
D O I：
10.2147/DDDT.S31442
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Tivozanib is a novel vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF TKI). Among other VEGF TKIs, tivozanib stands apart due to its selective kinase inhibitory properties as well as its high potency for inhibiting VEGF receptors 1 and 2. Tivozanib has been evaluated in several clinical trials including a Phase I and Phase II trial demonstrating safety and efficacy for patients with advanced clear cell renal cell carcinoma (RCC). A pivotal randomized Phase III trial comparing the front-line use of tivozanib to sorafenib in patients with metastatic clear cell RCC has been reported. The clinical development of tivozanib and results of these important studies will be reviewed. Also, the potential placement of tivozanib among currently US Food and Drug Administration approved agents for advanced RCC will be discussed.
引用
收藏
页码：519 / 527
页数：9
相关论文
共 30 条
[1]  
Bukowski R M, 2001, Semin Urol Oncol, V19, P148
[2]   VEGF as a key mediator of angiogenesis in cancer [J].
Carmeliet, P .
ONCOLOGY, 2005, 69 :4-10
[3]  
Eisen T, EUR SOC MED ONC 2012
[4]   Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111
[5]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[6]   Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival [J].
Escudier, Bernard ;
Bellmunt, Joaquim ;
Negrier, Sylvie ;
Bajetta, Emilio ;
Melichar, Bohuslav ;
Bracarda, Sergio ;
Ravaud, Alain ;
Golding, Sophie ;
Jethwa, Sangeeta ;
Sneller, Vesna .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2144-2150
[7]   Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Staehler, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Anderson, Sibyl ;
Hofilena, Gloria ;
Shan, Minghua ;
Pena, Carol ;
Lathia, Chetan ;
Bukowski, Ronald M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3312-3318
[8]  
Escudier BJ, 2012, J CLIN ONCOL S, V30
[9]   Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1,-2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors [J].
Eskens, Ferry A. L. M. ;
de Jonge, Maja J. A. ;
Bhargava, Pankaj ;
Isoe, Toshiyuki ;
Cotreau, Monette M. ;
Esteves, Brooke ;
Hayashi, Kunihiko ;
Burger, Herman ;
Thomeer, Maarten ;
van Doorn, Leni ;
Verweij, Jaap .
CLINICAL CANCER RESEARCH, 2011, 17 (22) :7156-7163
[10]  
Gartrell BA, 2012, J CLIN ONCOL, V30
123